Expedited transfer to a cardiac arrest centre for non-ST-elevation out-of-hospital cardiac arrest (ARREST): a UK prospective, multicentre, parallel, randomised clinical trial

>@**†**®

oa

Tiffany Patterson, Gavin D Perkins, Alexander Perkins, Tim Clayton, Richard Evans, Matthew Dodd, Steven Robertson, Karen Wilson. Adam Mellett-Smith, Rachael T Fothergill, Paul McCrone, Miles Dalby, Philip MacCart hy, Sam Firoazi, I abal Malik, Roby Rakhit, Ajay Jain, Jerry P Nolan, Simon R Redwood, for the ARREST trial collaborators*

Background The International Liaison Committee on Resuscitation has called for a randomised trial of delivery to a Long 2023; 402: 1329-37 cardiac arrest centre. We aimed to assess whether expedited delivery to a cardiac arrest centre compared with current standard of care following resuscitated cardiac arrest reduces deaths.

Methods ARREST is a prospective, parallel, multicentre, open-label, randomised superiority trial. Patients (aged ≥18 years) with return of spontaneous circulation following out-of-hospital cardiac arrest without ST elevation were randomly assigned (1:1) at the scene of their cardiac arrest by London Ambulance Service staff using a secure online randomisation system to expedited delivery to the cardiac catheter laboratory at one of seven cardiac arrest centres or standard of care with delivery to the geographically closest emergency department at one of 32 hospitals in London, UK. Masking of the ambulance staff who delivered the interventions and those reporting treatment outcomes in hospital was not possible. The primary outcome was all-cause mortality at 30 days, analysed in the intention-to-treat (ITT) population excluding those with unknown mortality status. Safety outcomes were analysed in the ITT population. The trial was prospectively registered with the International Standard Randomised Controlled Trials

Findings Between Ian 15, 2018, and Dec 1, 2022, 862 patients were enrolled, of whom 431 (50%) were randomly assigned to a cardiac arrest centre and 431 (50%) to standard care. 20 participants withdrew from the cardiac arrest Medical School University of centre group and 19 from the standard care group, due to lack of consent or unknown mortality status, leaving Waswick, Cosonby, UK 411 participants in the cardiac arrest centre group and 412 in the standard care group for the primary analysis. Of 822 participants for whom data were available, 560 (68%) were male and 262 (32%) were female. The primary endpoint of 30-day mortality occurred in 258 (63%) of 411 participants in the cardiac arrest centre group and in School of Hyginne & Tropical 258 (63%) of 412 in the standard care group (unadjusted risk ratio for survival 1-00, 95% CI 0-90-1-11; p=0-96). Eight (2%) of 414 patients in the cardiac arrest centre group and three (1%) of 413 in the standard care group had serious adverse events, none of which were deemed related to the trial intervention.

interpretation In adult patients without ST elevation, transfer to a cardiac arrest centre following resuscitated cardiac arrest in the community did not reduce deaths.

Funding British Heart Foundation.

Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0

Introduction

for OHCA management would work in a similar manner Resuscitation highlighted the need for a randomised trial.

to networks for ST-elevation invocardial infarction, with There are marked regional variations in survival following ambulance staff providing prompt identification and resuscitated out-of-hospital cardiac arrest (OHCA), which delivery of patients to a designated cardiac arrest centre. 10 are autibusable to resources, personnel, and infrastructure Post-arrest care with early interventions for ischaemiain addition to patient characteristics. 32 Regionalisation of reperfusion injury and treatment of the underlying cause (MDablyMD); Department of care improves outcomes in patients with time-critical has preferential outcomes.7 This care might be better filness by concentrating services within centres, delivered in a cardiac arrest centre; however, observational increasing the number of patients treated and therefore studies yield conflicting results due to confounding the skills and experience of health-care providers within variables, including selection bias and heterogenetw of those centres, Implementing prehospital systems of care are. As a result, the International Liaison Committee on

https://doi.org/10.1016/ 5014D-6736(23)01351-X

Collaborators are listed in the

Guy's and St Thomas' NHS Foundation Trust, London, UK (T Patterson PhD, KWilson MSc, Cardiovascular Department, Faculty of Life Sciences and Medicine, King's College London, London, UK (T Patterson, Prof S R Redwood); Clinical Trials Unit, Warwick London, UK (A Perkins M Sc. Clayton MSc, R Evans BA, M Dodd MSc, S Robertson BA) Clinical Audit and Research Unit, London Ambulance Service London UK (A Mellett-Smith MSc. Prof RT Fotheraill's Faculty of Health, Social Care and Education, Kingston University and St George's, University of London, London, UK (Prof RT Fothergill); Institute for Lifecourse Development, Brompton and Harefield NHS Foundation Trust London, UK Cardiology, King's College

(Prof P MacCarthy MD);

Department of Cardiology, St Georges Hospital London,






ARREST TRIAL

JIŘÍ KARÁSEK

FN MOTOL A 2.LF UK



The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)

It is recommended that post-resuscitation care is performed in high-volume expert centres capable of offering multidisciplinary intensive care treatment, including primary coronary interventions, electrophysiology, cardiac assist devices, cardiac and vascular surgery and therapeutic hypothermia.	-	В	245, 246
The creation of regional networks for the treatment of cardiac arrest should be considered to improve outcomes.	lla	В	245



Resuscitation



ournal homepage: www.elsevier.com/locate/resuscitation

European Resuscitation Council and European Society of Intensive Care Medicine Guidelines 2021: Post-resuscitation care*

Jerry P. Nolan^{a,b,1,*}, Claudio Sandroni^{c,d,1}, Bernd W. Böttiger^e, Alain Cariou^f, Tobias Cronberg^g, Hans Friberg^h, Cornelia Genbrugge^{i,j}, Kirstie Haywood^k, Gisela Lilja^l, Véronique R.M. Moulaert^m, Nikolaos Nikolaouⁿ, Theresa Mariero Olasveengen^o, Markus B. Skrifvars^p, Fabio Taccone^q, Jasmeet Soar^r

Cardiac arrest centres

No specific recommendation

Adult patients with non-traumatic OHCA should be considered for transport to a cardiac arrest centre according to local protocol.

An expert consensus paper published by several European organisations including the Association of Acute Cardiovascular Care

several European organisations including the Association of Acute Cardiovascular Care (ACVA) of the European Society of Cardiology (ESC), the ERC and the ESICM, states that the minimum requirements for a cardiac arrest centre are 24/7 availability of an on-site coronary angiography laboratory, an emergency department, an ICU, imaging facilities, such as echocardiography, CT, and MRI. ¹⁶
Based on evidence from a systematic review, ILCOR suggests that wherever possible, adult patients with non-traumatic OHCA cardiac arrest should be cared for in cardiac arrest centres. ¹⁷




European Heart Journal (2017) **38**, 1645–1652 doi:10.1093/eurheartj/eh×104

CLINICAL RESEARCH

Acute coronary syndromes

Distance to invasive heart centre, performance of acute coronary angiography, and angioplasty and associated outcome in out-of-hospital cardiac arrest: a nationwide study

Tinne Tranberg^{1*}, Freddy K. Lippert², Erika F. Christensen^{3,4}, Carsten Stengaard¹, Jakob Hjort¹, Jens Flensted Lassen¹, Frants Petersen⁵, Jan Skov Jensen⁶, Caroline Bäck⁷, Lisette Okkels Jensen⁸, Jan Ravkilde⁹, Hans Erik Bøtker¹, and Christian Juhl Terkelsen¹











Original Investigation | Emergency Medicine

Association of High-Volume Centers With Survival Outcomes Among Patients With Nontraumatic Out-of-Hospital Cardiac Arrest A Systematic Review and Meta-Analysis

Amelia Xin Chun Goh; Jie Cong Seow; Melvin Yong Hao Lai; Nan Liu, PhD; Yi Man Goh; Marcus Eng Hock Ong, MBBS, MPH; Shir Lynn Lim, MBBS, MMed (Int Med); Jamie Sin Ying Ho, MBBChir (Cantab); Jun Wei Yeo; Andrew Fu Wah Ho, MBBS, MMed, MPH

Figure 2. Adjusted Odds of Survival to Charge and to 30 Days

	log[Odds			Favors ! Favors	
Study or subgroup	ratio]	SE	OR (95% CI)	low volume high volume	Weight, %
Survival to discharge				İ	
Balian et al, ¹⁷ 2019	0.36	0.14	1.43 (1.08-1.89)	-	10.5
Callaway et al, ¹⁸ 2010	0.09	0.16	1.10 (0.80-1.50)	-	10.2
Cha et al, ¹⁹ 2012	1.01	0.13	2.74 (2.12-3.54)		10.8
Chocron et al, ²⁰ 2017	0.24	0.35	1.27 (0.64-2.51)		6.3
Couper et al., 21 2018	0.03	0.18	1.03 (0.72-1.47)	—	9.7
Cudnik et al, ²² 2012	-0.03	0.15	0.97 (0.73-1.29)	-	10.5
Shin et al, ²⁹ 2011	0.59	0.12	1.81 (1.43-2.30)	-	11.0
Stub et al, ³⁰ 2011	0.02	0.19	1.02 (0.70-1.48)	-	9.5
von Vopelius-Feldt et al, ³¹ 2021	0.34	0.11	1.41 (1.14-1.75)	-■ -	11.2
Subtotal (95% CI)			1.36 (1.08-1.73)		89.7
Heterogeneity: $\tau^2 = 0.10$; $\chi^2 = 44.62$, $df = 8 (P < .001)$; $t^2 = 82\%$					
Test for overall effect: $z = 2.57$ ($P = .01$)					
Survival to 30 d					
Kashiura et al, ²³ 2020	-0.27	0.15	0.76 (0.56-1.03)	-■ -	10.3
Subtotal (95% CI)			0.76 (0.56-1.03)	\Diamond	10.3
Heterogeneity: Not applicable Test for overall effect: z = 1.79 (P = .07)					
			1.28 (1.00-1.64)		100.0
Total (95% CI)			1.28 (1.00-1.04)		100.0
Heterogeneity: $\tau^2 = 0.13$; $\chi^2 = 60.62$, $df = 9 (P < .001)$; $l^2 = 85\%$				 	
Test for overall effect: $z = 1.97$ ($P = .05$) Test for subgroup differences: $\chi^2 = 9.00$, $df = 1$ ($P = .003$); $I^2 = 88$	980		(0.5 1	5
ics. io surgroup unicicis. 2 - 3.00, 0 - 1 (F003); F - 00	.276			OR (95% CI)	


Figure 3. Adjusted Odds of Good Neurological Outcomes at Discharge and 30 Days

itudy or subgroup	log[Odds ratio]	SE	OR (95% CI)	Favors Favors low volume high volume	Weight, %
ood neurological outcomes at discharge					_
Balian et al, ¹⁷ 2019	0.41	0.15	1.51 (1.11-2.05)		12.8
Couper et al, 21 2018	-0.06	0.17	0.94 (0.67-1.32)	+	12.1
Cudník et al, ²² 2012	-0.97	0.28	0.38 (0.22-0.66)		8.3
Lee et al, ²⁵ 2015	-0.41	0.28	0.66 (0.39-1.14)	 ∔	8.4
Mumma et al, ²⁶ 2015	0.28	0.11	1.32 (1.06-1.64)	+	14.5
Schober et al, ²⁸ 2016	1.65	0.74	5.20 (1.22-22.11)	ļ——	2.1
Worthington et al, 32 2017	-0.14	0.08	0.87 (0.74-1.02)	•	15.5
Subtotal (95% CI)			0.98 (0.71-1.33)	\(\langle	73.4
Test for overall effect: z = 0.16 (P = .88) ood neurological outcomes at 30 d					
Kashiura et al, ²³ 2020	-0.26	0.19	0.77 (0.53-1.12)		11.4
Matsuyama et al, ²⁵ 2017	0.03	0.09	1.03 (0.87-1.22)	+	15.2
Subtotal (95% CI)			0.94 (0.72-1.22)	•	26.6
				İ	
Heterogeneity: $\tau^2 = 0.02$; $\chi^2 = 1.91$, df = 1 ($P = .17$); $I^2 = 48\%$ Test for overall effect: $z = 0.49$ ($P = .63$)					
			0.96 (0.77-1.20)	•	100.0



- Multicentrická otevřená, randomizovaná studie
- (2018-2022), přerušená pro COVID
- Inclusion: věk nad 18, ROSC,
 předpokládaná kard. zástava, EKG bez
 ST elevací
- Exclusion: těhotenství, předpokládaná nekard. etiologie, ST elevace na EKG po KPR
- Randomizace 1:1 (7x cathlab CAC vs.
 32 ED nejbližší nemocnice)
- Primární endpoint: 30- denní mortalita
- Sekundární endpointy: 3-měsíční mortalita, neurolog. status při dimisi a 3.měsíc





	Cardiac arrest centre group (n=414)	Standard care group (n=413)
Age, years	63.8 (16)	63.2 (16)
Sex		
Male	285/412 (69%)	275/410 (67%)
Female	127/412 (31%)	135/410 (33%)
Ethnicity		
White	224/414 (54%)	224/413 (54%)
Asian	69/414 (17%)	69/413 (17%)
Afro-Caribbean	21/414 (5%)	25/413 (6%)
Other	39/414 (9%)	45/413 (11%)
Notknown	61/414 (15%)	50/413 (12%)
Medical history		
Diabetes	98/385 (26%)	90/376 (24%)
Hypertension	182/376 (48%)	190/372 (51%)
Smoking status		
Neversmoked	96/414 (23%)	83/413 (20%)
Ex-smoker	50/414 (12%)	53/413 (13%)
Current smoker	41/414 (10%)	55/413 (13%)
Notknown	227/414 (55%)	222/413 (54%)
Hypercholesterolaemia	99/342 (29%)	83/315 (26%)
Peripheral vascular disease	12/360 (3%)	13/348 (4%)
Cerebrovascular disease	26/369 (7%)	39/362 (11%)
Chronic renal failure	33/375 (9%)	31/362 (9%)
Known ischaemic heart disease	83/362 (23%)	63/353 (18%)
Previous myocardial infarction	54/364 (15%)	48/362 (13%)
Previous percutaneous coronary intervention	46/362 (13%)	34/349 (10%)
Family history of heart disease	32/179 (18%)	32/168 (19%)
Preceding symptoms before cardiac arrest	122/267 (46%)	142/260 (55%)
Chest pain	29/122 (24%)	43/142 (30%)
Dizziness	11/122 (9%)	29/142 (20%)
Breathlessness	50/122 (41%)	49/142 (35%)
Palpitations	2/122 (2%)	8/142 (6%)
Other symptoms	61/122 (50%)	74/142 (52%)

Data are mean (SD) or n/N (%). Ethnicity and smoking status had "Not known" a a response category in the case report form and so the denominator for these variables is the total number of patients in the intention-to-treat population; other variables did not have this option, and therefore the denominator for all other variables is the number of patients for whom data were available.

Table 1: Baseline characteristics of the intention-to-treat population

Location of arrest Private 208 (50%) 242 (59%) Public 206 (50%) 171 (41%)
Public 206 (50%) 171 (41%) Witnessed arrest Bystander 308 (74%) 307 (74%) LAS 30 (7%) 25 (6%) Not witnessed 76 (18%) 81 (20%) Presenting cardiac rhythm AED non-shockable, asystole, or PEA 184 (44%) 188 (46%) AED shockable, VF, or pulseless VT 229 (55%) 225 (55%) Not known 1 (<1%) 0 Initial CPR attempt Bystander 290 (70%) 313 (76%)
Witnessed arrest Bystander 308 (74%) 307 (74%) LAS 30 (7%) 25 (6%) Not witnessed 76 (18%) 81 (20%) Presenting cardiac rhythm AED non-shockable, asystole, or PEA 184 (44%) 188 (46%) AED shockable, VF, or pulseless VT 229 (55%) Not known 1 (<1%) 0 Initial CPR attempt Bystander 290 (70%) 313 (76%)
Bystander 308 (74%) 307 (74%) LAS 30 (7%) 25 (6%) Not witnessed 76 (18%) 81 (20%) Presenting cardiac rhythm AED non-shockable, asystole, or PEA 184 (44%) 188 (46%) AED shockable, VF, or pulseless VT 229 (55%) Not known 1 (<1%) 0 Initial CPR attempt Bystander 290 (70%) 313 (76%)
LAS 30 (7%) 25 (6%) Not witnessed 76 (18%) 81 (20%) Presenting cardiac rhythm AED non-shockable, asystole, or PEA 184 (44%) 188 (46%) AED shockable, VF, or pulseless VT 229 (55%) 225 (55%) Not known 1 (<1%)
Not witnessed 76 (18%) 81 (20%) Presenting cardiac rhythm AED non-shockable, asystole, or PEA 184 (44%) 188 (46%) AED shockable, VF, or pulseless VT 229 (55%) 225 (55%) Not known 1 (<1%)
Presenting cardiac rhythm AED non-shockable, asystole, or PEA 184 (44%) 188 (46%) AED shockable, VF, or pulseless VT 229 (55%) 225 (55%) Not known 1 (<1%) 0 Initial CPR attempt Bystander 290 (70%) 313 (76%)
AED non-shockable, asystole, or PEA 184 (44%) 188 (46%) AED shockable, VF, or pulseless VT 229 (55%) 225 (55%) Not known 1 (<1%) 0 Initial CPR attempt Bystander 290 (70%) 313 (76%)
AED shockable, VF, or pulseless VT 229 (55%) 225 (55%) Not known 1 (<1%)
Not known 1 (<1%) 0 Initial CPR attempt 290 (70%) 313 (76%)
Initial CPR attempt Bystander 290 (70%) 313 (76%)
Bystander 290 (70%) 313 (76%)
LAS 123 (30%) 100 (24%)
Not performed 1 (<1%) 0
Time from arrest to LAS CPR start, min 9 (7–12); n=278 10 (7–12); n=275
First defibrillation performed
Public access defibrillator 49 (12%) 54 (13%)
LAS 211 (51%) 198 (48%)
Not performed 142 (34%) 150 (36%)
Not known 12 (3%) 11 (3%)
Time from arrest to first defibrillation, min 10 (7–14); n=194 11 (7–14); n=199
Number of shocks delivered 2 (1-4); n=242 2 (1-3); n=226
Adrenaline administered 267 (65%) 260 (63%)
Adrenaline dose, mg 2 (1-4); n=260 2 (1-4); n=254
Amiodarone administered 68 (16%) 58 (14%)
Amiodarone dose, mg 300 (300-300); n=65 300 (300-300); n=52
Mechanical CPR 100/412 (24%) 93/411 (23%)
Time from arrest to ROSC, mins 24 (15–33); n=310 25 (16–34); n=314
Field termination of resuscitation 2 (1%) 3 (1%)
Time from arrest to hospital arrival, min 84 (68–104); n=332 77 (63–96); n=328
Post-ROSC electrocardiogram*
ST-segment elevation 7 (2%) 5 (1%)
Bundle branch block 116 (28%) 99 (24%)
ST-segment depression or T wave changes (or both) 156 (38%) 181 (44%)
No acute changes 91 (22%) 83 (20%)
No electrocardiogram 44 (11%) 45 (11%)

Data are n (%), median (IQR), or n/N (%). The number of participants for whom data were obtained is presented after median values and n values when the number was less than the total intention-to-teat population. AED=automated external defibrillator. CPR=cardiopulmonary resuscitation. LAS=London Ambulance Service. PEA=pulseless electrical activity. ROSC=return of spontaneous circulation. VF=ventricular fibrillation. VT=ventricular tachycardia.

Table 2: Prehospital key events in the intention-to-treat population

arrest is provided in the appendix (pp 33–34). A cardiac cause of arrest was identified in 260 (63%) of 414 patients in the cardiac arrest centre group and 245 (59%) of 413 patients in the standard care group. In patients with a

vs 93 [23%] of 406). A higher proportion of patients in the cardiac arrest centre group than in the standard care group were admitted to intensive care (330 [80%] of 414 vs 286 [69%] of 413), received haemodynamic support (297 [72%] of 412 vs 252 [62%] of 406), ventilatory support (353 [86%] of 412 vs 312 [76%] of 410), and renal support (46 [11%] of 411 vs 34 [8%] of 403). A higher proportion of patients in the cardiac arrest centre group than in the standard care group had coronary angiography (231 [56%] of 412 vs 153 [37%] of 410). The median time to

London Ambulance Service cardiac arrest annual audit data, resuscitation is attempted in

approximately 36% of all out-of-hospital cardiac arrests. Resuscitation can be withheld if

^{*}The electrocardiogram was reviewed independently after trial enrolment and randomisation. Defibrillation data were analysed for patients with shockable rhythm only.

mRS score at discharge 0R 1-00 0-99 (0-76 to 1-32) 0 70/413 (17%) 78/402 (19%)	
Total color	
3-month mortality	o 6·8)
mortality mR5 score at discharge 0 70/413 (17%) 78/402 (19%)	
discharge (0.76 to 1-32) 0 70/413 (17%) 78/402 (19%) 1 23/413 (6%) 31/402 (8%) 2 22/413 (5%) 12/402 (3%) 3 15/413 (4%) 9/402 (2%) 4 10/413 (2%) 2/402 (1%)	o 7·5%)
1 23/413 (6%) 31/402 (8%)	
2 22/413 (5%) 12/402 (3%)	
3 15/413 (4%) 9/402 (2%) ·· · · · · · · · · · · · · · · · · ·	
4 10/413 (2%) 2/402 (1%)	
5 45/442/480 42/402/280	
5 16/413 (4%) 12/402 (3%)	
6 257/413 (62%) 258/402 (64%)	
mRS score at OR 0-98 0-87	
3 months (0.73 to 1.31)	
0 75/399 (19) 69/390 (18%)	
1 22/399 (6%) 32/390 (8%)	
2 17/399 (4%) 9/390 (2%)	
3 5/399 (1%) 9/390 (2%)	
4 9/399 (2%) 3/390 (1%)	
5 4/399 (1%) 5/390 (1%)	
6 267/399 (67%) 263/390 (67%)	
mRS score at discharge	
Favourable 130/413 (32%) 130/402 (32%) RR 1-01 0-79 0-9%	
(0-92 to 1-11) (-5-5 to	7-3)
Unfavourable 283/413 (69%) 272/402 (68%)	
mRS score at 3 months	
Favourable 119/399 (30%) 119/390 (31%) RR 1·01 0·83 0·7% (0·92 to 1·11) (-5·7 to	7.4
Unfavourable 280/399 (70%) 271/390 (70%)	0/-1)
score n=97† n=92† -0.04 (-0.12 to 0.05)	0/-1)

Data are r/N (%) and mean (SD), unless otherwise specified. Mortality refers to all-cause mortality. mRS=modified Rankin Scale. OR=odds ratio. RR=risk ratio. *Adjusted OR calculated due to convergence issues. †The number of participants for whom data were obtained.

Table 3: Primary and secondary outcomes




Table 3: Out-of-hospital cardiac arrest volume and survival in London per centre (2017-18).

Cardiac Arrest Centre	Number of patients	Survival
	Median 125 (IQR 100 to 167)	Mean 45.7% (±0.1)
St Thomas Hospital	112	47.8% (32/67)
Barts Heart Centre	125	55.8% (53/95)
King's College Hospital	189	36.5% (46/126)
Harefield Hospital	61	54.2% (26/48)
St George's Hospital	184	36.4% (47/129)
Royal Free Hospital	150	42.5% (45/106)
Hammersmith Hospital	88	47% (31/66)
Non-CAC	Number of patients	Survival
	Median 62 (IQR 44 to 79)	Mean 14.4% (±0.1)
Barnet Hospital	50	26.1% (6/23)
Northwick Park Hospital	110	9.6% (5/52)
Hillingdon Hospital	68	15.8% (6/38)
Queens Hospital, Romford	(119)	9.6% (5/52)
University College Hospital	34	26.7% (4/15)
Homerton Hospital	44	4.8% (1/21)
Ealing Hospital	56	16.7% (5/30)

Queen Elizabeth Hospital	107	15.9% (7/44)
North Middlesex Hospital	107	17.3% (9/52)
West Middlesex Hospital	78	9.4% (3/32)
Whittington Hospital	32	18.8% (3/16)
Kingston Hospital	64	16.1% (5/31)
University Hospital Lewisham	58	17.2% (5/29)
St Helier Hospital	44	10% (2/20)
Newham Hospital	80	10.3% (3/29)
St Mary's Hospital	70	25.7% (9/35)
King George Hospital	57	4.8% (1/21)
Charing Cross Hospital	34)	9.1% (1/11)
Chelsea & Westminster Hospital	33	27.8% (5/18)
Princess Royal Hospital	59	3.1% (1/32)
Croydon University Hospital	69	14.7% (5/34)
Darent Valley Hospital	11)	0% (0/4)
Watford Hospital	Unavailable	Unavailable
Royal London Hospital	86	18.4% (7/38)
Whipps Cross Hospital	76	16.7% (5/30)
Central Middlesex Hospital	Unavailable	Unavailable
Chase Farm Hospital	Unavailable	Unavailable
East Surrey Hospital	Unavailable	Unavailable







- Není rozdíl v 30 denním přežívání při umístění pacienta po OHCA s ROSC bez ST elevací do cardiac arrest centra vs. nejbližší nemocnice
- Rovněž není rozdíl v 3 měsíčním přežívání a dobrém neurologickém výsledku
- Pacienti přijímaní do CAC jsou více přijímáni na JIP, vyžadují více oběh., ventil. podporu a RRT bez vlivu na mortalitu a mají více koronarografií
- V subanalýze pacienti maldší 57 let profitují stran mortality více z CAC, ve věku 57-71 let z lok. nemocnice



My Lords, any state is better than despair. Let us at least make one effort; and if we must fall, let us fall like men!

After delivering this speech
Chatham suddenly pressed his hand to his heart and fell back in a swoon.